Yoshikazu Nakaoka, Mitsuaki Isobe, Yoshiya Tanaka, Tomonori Ishii, Seido Ooka, Hiroaki Niiro, Naoto Tamura, Shogo Banno, Hajime Yoshifuji, Yasushi Sakata, Atsushi Kawakami, Tatsuya Atsumi, Shunsuke Furuta, Hitoshi Kohsaka, Katsuya Suzuki, Ryoki Hara, Yasuhiro Maejima, Hiroshi Tsukamoto, Yoshinari Takasaki, Katsuhisa Yamashita, Norihiro Okada, Shinji Yamakido, Syuji Takei, Shumpei Yokota, Norihiro Nishimoto
OBJECTIVE: To investigate the long-term efficacy and safety of the IL-6 receptor antibody tocilizumab in patients with Takayasu arteritis (TAK). METHODS: Patients completing the randomized, double-blind, placebo-controlled period of the TAKT (Takayasu arteritis Treated with Tocilizumab) trial were followed up during open-label extended treatment with weekly s.c. tocilizumab 162 mg for up to 96 weeks or longer, with oral glucocorticoid tapering performed at the investigators' discretion...
January 17, 2020: Rheumatology
Laura S van Dam, Zgjim Osmani, Sylvia W A Kamerling, Tineke Kraaij, Jaap A Bakker, Hans U Scherer, Ton J Rabelink, Reinhard E Voll, Tobias Alexander, David A Isenberg, Cees van Kooten, Y K Onno Teng
OBJECTIVES: SLE is a severe autoimmune disease characterized by autoreactive B cells and IC formation, which causes systemic inflammation. B cell-targeted therapy could be a promising treatment strategy in SLE patients; nevertheless, randomized clinical trials have not always been successful. However, some groups have demonstrated beneficial effects in severe SLE patients with off-label rituximab (RTX) with belimumab (BLM), or bortezomib (BTZ), which targeted different B cells subsets...
January 17, 2020: Rheumatology
Jerome Razanamahery, Flora Dresco, Jean Francois Emile, Frank Verhoeven, Marie Paiule Algros, Juliette Lodovichetti, Sebastien Humbert, Kevin Bouiller, Nadine Magy-Bertrand
No abstract text is available yet for this article.
January 16, 2020: Rheumatology
Massimo Radin, Karen Schreiber, Irene Cecchi, Alessandra Bortoluzzi, Francesca Crisafulli, Cristiano M de Freitas, Beatrice Bacco, Elena Rubini, Silvia G Foddai, Melissa Padovan, Silvia Gallo Cassarino, Franco Franceschini, Danieli Andrade, Chiara Benedetto, Marcello Govoni, Tiziana Bertero, Luca Marozio, Dario Roccatello, Laura Andreoli, Savino Sciascia
OBJECTIVES: To investigate fetal/perinatal and maternal outcomes from a large multicentre cohort of women diagnosed with UCTD. METHODS: This multicentre retrospective cohort study describes the outcomes of 224 pregnancies in 133 consecutive women with a diagnosis of UCTD, positive for ANA and aged <45 years old at study inclusion. RESULTS: Of the 224 pregnancies analysed, 177 (79%) resulted in live births, 45 (20.1%) in miscarriages (defined as pregnancy loss before 12 weeks' gestation), 2 (0...
January 14, 2020: Rheumatology
Ruchika Goel, Katherine Bates Gribbons, Peter A Merkel, Debashish Danda, Peter C Grayson
No abstract text is available yet for this article.
January 14, 2020: Rheumatology
Jennifer S Gregory, Rebecca J Barr, Kanako Yoshida, Salvatore Alesci, David M Reid, Richard M Aspden
OBJECTIVES: Responsive biomarkers are needed to assess the progression of OA and their lack has hampered previous clinical trials. Statistical shape modelling (SSM) from radiographic images identifies those at greatest risk of fast-progression or joint replacement, but its sensitivity to change has not previously been measured. This study evaluates the responsiveness of SSM in knee OA in a 12-month observational study. METHODS: A total of 109 people were recruited who had undergone knee radiographs in the previous 12 months, and were grouped based on severity of radiographic OA (Kellgren-Lawrence grading)...
January 14, 2020: Rheumatology
Azeem Ahmed, Khin Yein, Elizabeth Price
No abstract text is available yet for this article.
January 14, 2020: Rheumatology
Durga Prasanna Misra, Vikas Agarwal, Aman Sharma
No abstract text is available yet for this article.
January 14, 2020: Rheumatology
Veronika Sebestyén, Gabriella Szűcs, Dénes Páll, Dóra Ujvárosy, Tamás Ötvös, Imre Csige, Tamás Pataki, István Lőrincz, Zoltán Szabó
SSc is an autoimmune disease characterized by microvascular damage, endothelial dysfunction and fibrosis of the skin and the internal organs. Cardiac manifestation in patients with SSc is one of the major organ involvements. Approximately 20% of SSc patients suffer from primary cardiovascular disease and another 20% may have secondary cardiac involvement. Although cardiac arrhythmias are mostly linked to myocardial fibrosis, atrioventricular conduction abnormalities are secondary to the fibrosis of the pulse conduction system...
January 14, 2020: Rheumatology
Raj Amarnani, Simon Travis, Muhammad Kassim Javaid
No abstract text is available yet for this article.
January 13, 2020: Rheumatology
Rakesh Kumar Pilania, Swetha Palla, Pandiarajan Vignesh, Ritamabara Nada, Surjit Singh
No abstract text is available yet for this article.
January 13, 2020: Rheumatology
Sabrina Paolino, Federica Goegan, Carmen Pizzorni, Alberto Sulli, Vanessa Smith, Maurzio Cutolo, Greta Pacini
No abstract text is available yet for this article.
January 13, 2020: Rheumatology
S Rostami, M Hoff, M A Brown, K Hveem, V Videm
OBJECTIVES: To evaluate selection methods among published single-nucleotide polymorphisms (SNPs) associated with RA to construct predictive genetic risk scores (GRSs) in a population-based setting. METHODS: The Nord-Trøndelag Health (HUNT) Study is a prospective cohort study among the whole adult population of northern Trøndelag, Norway. Participants in HUNT2 (1995-1997) and HUNT3 (2006-2008) were included (489 RA cases, 61 584 controls). The initial SNP selection from relevant genome-wide studies included 269 SNPs from 30 studies...
January 13, 2020: Rheumatology
Kohei Karino, Michihiro Kono, Michihito Kono, Keita Sakamoto, Yuichiro Fujieda, Masaru Kato, Olga Amengual, Kenji Oku, Shinsuke Yasuda, Tatsuya Atsumi
OBJECTIVE: Rapidly progressive interstitial lung disease (RPILD) is a major cause of death in patients with DM. Although clinically amyopathic DM (CADM) represents risk for RPILD, the incidence rate of RPILD in patients with CADM varies widely. Whole-body (WB) MRI can reveal involvement of systemic muscle and myofascia. The objective of this study was to explore the risk factors for RPILD in patients with DM using WB-MRI. METHODS: This retrospective study comprised 41 patients with DM who underwent WB-MRI before the initiation of treatment in our hospital...
January 10, 2020: Rheumatology
Elham Rezaei, Daniel Hogan, Brett Trost, Anthony J Kusalik, Gilles Boire, David A Cabral, Sarah Campillo, Gaëlle Chédeville, Anne-Laure Chetaille, Paul Dancey, Ciaran Duffy, Karen Watanabe Duffy, John Gordon, Jaime Guzman, Kristin Houghton, Adam M Huber, Roman Jurencak, Bianca Lang, Kimberly Morishita, Kiem G Oen, Ross E Petty, Suzanne E Ramsey, Rosie Scuccimarri, Lynn Spiegel, Elizabeth Stringer, Regina M Taylor-Gjevre, Shirley M L Tse, Lori B Tucker, Stuart E Turvey, Susan Tupper, Rae S M Yeung, Susanne Benseler, Janet Ellsworth, Chantal Guillet, Chandima Karananayake, Nazeem Muhajarine, Johannes Roth, Rayfel Schneider, Alan M Rosenberg
OBJECTIVE: To identify early predictors of disease activity at 18 months in JIA using clinical and biomarker profiling. METHODS: Clinical and biomarker data were collected at JIA diagnosis in a prospective longitudinal inception cohort of 82 children with non-systemic JIA, and their ability to predict an active joint count of 0, a physician global assessment of disease activity of ≤1 cm, and inactive disease by Wallace 2004 criteria 18 months later was assessed...
January 9, 2020: Rheumatology
Anouk M Barendregt, Saskia R Veldkamp, Petra C E Hissink Muller, Annemarie van de Geer, Cathelijn Aarts, E Charlotte van Gulik, Marco W Schilham, Christoph Kessel, Mischa P Keizer, Robert Hemke, Amara Nassar-Sheikh Rashid, Koert M Dolman, Dieneke Schonenberg-Meinema, Rebecca Ten Cate, J Merlijn van den Berg, Mario Maas, Taco W Kuijpers
OBJECTIVE: To study two neutrophil activation markers, myeloid-related protein (MRP) 8/14 and neutrophil elastase (NE), for their ability to predict treatment response and flare in patients with JIA. METHODS: Using samples from two cohorts (I and II), we determined MRP8/14 and NE levels of 32 (I) and 81 (II) patients with new-onset, DMARD-naïve arthritis and compared patients who responded to treatment (defined as fulfilling ≥ adjusted ACRpedi50 response and/or inactive disease) with non-responders (defined as fulfilling < adjusted ACRpedi50 response and/or active disease) at 6 and 12 months...
January 6, 2020: Rheumatology
Se Gwang Jang, Jaeseon Lee, Seung-Min Hong, Seung-Ki Kwok, Mi-La Cho, Sung-Hwan Park
OBJECTIVES: Mesenchymal stem cells (MSCs) are considered potential therapeutic agents for treating autoimmune disease because of their immunomodulatory capacities and anti-inflammatory effects. However, several studies have shown that there is no consistency in the effectiveness of the MSCs to treat autoimmune disease, including SLE. In this study, we investigated whether metformin could enhance the immunoregulatory function of MSCs, what mechanism is relevant, and whether metformin-treated MSCs could be effective in an animal lupus model...
January 6, 2020: Rheumatology
Lewis Carpenter, Elena Nikiphorou, Patrick D W Kiely, David A Walsh, Adam Young, Sam Norton
OBJECTIVES: To examine secular trends in the progression of clinical and patient-reported outcomes in early RA. METHODS: A total of 2701 patients recruited to the Early Rheumatoid Arthritis Study or Early Rheumatoid Arthritis Network with year of diagnosis from 1986 to 2011. The 5-year progression rates for patients diagnosed at different points in time were modelled using mixed-effects regression; 1990, 2002 and 2010, were compared. Clinical markers of disease included the 28-joint count DAS and the ESR...
January 3, 2020: Rheumatology
Hua-Zhi Ling, Shu-Zhen Xu, Rui-Xue Leng, Jun Wu, Hai-Feng Pan, Yin-Guang Fan, Bin Wang, Yuan-Rui Xia, Qian Huang, Zong-Wen Shuai, Dong-Qing Ye
OBJECTIVE: Clinical diagnosis of SLE is currently challenging due to its heterogeneity. Many autoantibodies are associated with SLE and are considered potential diagnostic markers, but systematic screening and validation of such autoantibodies is lacking. This study aimed to systematically discover new autoantibodies that may be good biomarkers for use in SLE diagnosis. METHODS: Sera from 15 SLE patients and 5 healthy volunteers were analysed using human proteome microarrays to identify candidate SLE-related autoantibodies...
January 3, 2020: Rheumatology
Fabio Cacciapaglia, Simone Perniola, Livio Urso, Marco Fornaro, Florenzo Iannone
No abstract text is available yet for this article.
January 3, 2020: Rheumatology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"